Exchange Traded Concepts LLC Lowers Stake in Bristol Myers Squibb Company $BMY

Exchange Traded Concepts LLC lessened its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 81.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 116,233 shares of the biopharmaceutical company’s stock after selling 523,740 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Bristol Myers Squibb were worth $6,270,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bath Savings Trust Co lifted its holdings in shares of Bristol Myers Squibb by 2.3% during the fourth quarter. Bath Savings Trust Co now owns 8,743 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 198 shares during the last quarter. Albert D Mason Inc. grew its stake in shares of Bristol Myers Squibb by 3.0% in the 4th quarter. Albert D Mason Inc. now owns 7,236 shares of the biopharmaceutical company’s stock worth $390,000 after buying an additional 213 shares during the last quarter. CVA Family Office LLC increased its position in Bristol Myers Squibb by 2.6% during the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 223 shares in the last quarter. MSH Capital Advisors LLC raised its stake in Bristol Myers Squibb by 2.9% during the third quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company’s stock valued at $362,000 after buying an additional 223 shares during the last quarter. Finally, Bell & Brown Wealth Advisors LLC raised its stake in Bristol Myers Squibb by 0.5% during the third quarter. Bell & Brown Wealth Advisors LLC now owns 42,691 shares of the biopharmaceutical company’s stock valued at $1,925,000 after buying an additional 224 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent research reports. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a research note on Wednesday, December 3rd. Barclays began coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target for the company. Scotiabank reissued a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Nine equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.41.

Bristol Myers Squibb Price Performance

BMY opened at $58.59 on Monday. The company’s 50-day simple moving average is $58.82 and its two-hundred day simple moving average is $52.27. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The stock has a market capitalization of $119.62 billion, a P/E ratio of 16.98, a P/E/G ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the prior year, the firm earned $1.67 earnings per share. The business’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is 73.04%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 data for Camzyos (mavacamten) in adolescents — SCOUT‑HCM showed efficacy and safety in teens with symptomatic obstructive hypertrophic cardiomyopathy, supporting a potential label expansion and added addressable market for an established cardiovascular product. This is a clear pipeline upside that could lift long‑term revenue expectations. Bristol Myers Presents Positive SCOUT‑HCM Results
• Positive Sentiment: Supportive real‑world/switch data for Cobenfy — Phase 4/open‑label switch results indicate symptom stability and acceptable tolerability when patients transition from other oral atypical antipsychotics to Cobenfy (xanomeline + trospium). These data help the schizophrenia franchise by reducing switching risk and may aid uptake. Open‑Label Switch Study for Cobenfy
• Neutral Sentiment: Investor write‑ups and buy theses highlight valuation and dividend appeal — recent articles argue BMY’s P/E and forward metrics, plus dividend yield and upcoming ex‑dividend timing, make the stock attractive for income/value investors, which can support a base under the share price but may not trigger rapid re‑rating. Is BMY a Good Stock to Buy?
• Neutral Sentiment: Ex‑dividend timing noted — coverage points out BMY goes ex‑dividend soon, which can attract short‑term dividend seekers but has limited fundamental impact. BMY Looks Like A Good Stock, Ex‑Dividend Soon
• Neutral Sentiment: Mixed analyst sentiment — roughly 60% of covering analysts show mixed ratings even though the consensus price target (~$63) implies modest upside; this split can cap near‑term momentum until clearer fundamentals emerge. Mixed Analyst Sentiment
• Negative Sentiment: Fundamental headwinds remain from prior earnings and guidance dynamics — recent quarterly EPS missed expectations and FY‑2026 guidance is below some street forecasts, which keeps near‑term valuation under pressure and helps explain downward stock moves despite clinical positives. (Background company filings and recent results.)

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.